Eli Lilly's shortage of diabetes and obesity drugs is over, halting competition with knock-offs
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have been producing copycat versions of the in-demand treatments.
The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...
Texas is suing insulin manufacturers and PBMs, including Eli Lilly and CVS Pharmacy, alleging a scheme to hike insulin prices ...
Lilly will add the center to a site in Lebanon, Indiana, where it is already spending about $9 billion to improve ...
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are ...
Texas Attorney General Ken Paxton's office said on Thursday it had sued insulin makers Eli Lilly, Novo Nordisk and Sanofi.
Drugmaker Eli Lilly announced it would be cutting some insulin prices by 70% and setting a $35 cap on monthly out-of-pocket ...
Pharmaceutical company Eli Lilly ($LLY) says it will spend $4.5 billion to create a new research and manufacturing center for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback